糖原合成酶激酶3β (GSK-3β) 抑制剂 - 专利更新 (2019-2024)
Swanand Vinayak Joshi1, Devandla Soujanya1, Manchella Sai Supriya1
1Department of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Expert opinion on therapeutic patents
|July 22, 2025
概括
糖原合成酶激酶-3β (GSK-3β) 抑制剂在治疗糖尿病,阿尔茨海默病和癌症等疾病方面表现有前途. 最近的专利文献 (2019-2024) 突出了具有治疗潜力的新型化合物.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖原合成酶激酶-3β (GSK-3β) 是糖原生物合成中的关键酶,涉及糖尿病,阿尔茨海默病和癌症.
- 过度表达GSK-3β突出其在疾病病理生理学中的关键作用,使其成为治疗点.
研究的目的:
- 从2019年到2024年审查关于GSK-3β抑制剂的专利文献.
- 讨论有希望的GSK-3β抑制剂的临床开发状态.
主要方法:
- 对专利数据库进行全面的文献搜索.
- 分析GSK-3β抑制剂的化学结构和生物特征.
- 对特定抑制剂的临床试验数据的审查.
主要成果:
- 许多天然和合成的异环化合物表现出GSK-3β抑制作用.
- 虽然许多化合物显示出潜力,但很少有进展到临床开发.
- 最近的专利揭示了具有有前途的治疗应用的新型GSK-3β抑制剂.
结论:
- 对于各种疾病,GSK-3β仍然是一个重要的治疗点.
- 进一步开发已识别的异环化合物可能会导致新的治疗方法.
- 专利格局表明GSK-3β抑制剂研究中的持续创新.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262
Glucagon-like Receptor Agonists
421
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
421
Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
265
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
265
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K


